cancer
one
formid
health
burden
increas
annual
frequenc
worldwid
spite
preclud
mani
caus
risk
factor
cancer
still
give
rise
death
world
everi
year
second
lead
caus
death
next
heart
diseas
current
avail
cancer
therapi
usual
suffer
poor
select
normal
invad
cell
seriou
side
effect
develop
drug
resist
therefor
continu
search
identifi
novel
antitumor
compound
bestow
low
toxic
minimum
side
effect
remain
critic
import
isatin
moieti
constitut
backbon
number
agrochem
dye
bioactiv
molecul
owe
appropri
size
uniqu
electron
properti
variou
isatin
util
anticanc
drug
drug
surrog
exampl
class
isatin
deriv
sunitinib
sutenttm
pfizer
inc
fig
clinic
approv
use
standard
firstlin
treatment
manag
gastrointestin
stromal
cancer
renal
cell
carcinoma
due
multitarget
tyrosin
kinas
inhibit
activ
nintedanib
fig
anoth
potenti
anticanc
agent
class
possess
tripl
angiokinas
inhibit
activ
toward
vascular
endotheli
growth
factor
receptor
vegfr
plateletderiv
growth
factor
receptor
pdgfr
fibroblast
growth
factor
receptor
fgfr
semaxanib
fig
develop
new
anticanc
candid
multipl
tyrosinekinas
receptor
inhibitor
activ
valu
less
nm
nci
cell
line
discontinu
clinic
trial
owe
danger
side
effect
schiff
base
isatin
acknowledg
broad
spectrum
biolog
activ
includ
anticonvuls
antibacteri
antifung
antihiv
antivir
anticanc
activ
indirubin
fig
bisisatin
isom
wide
use
color
indigo
fig
activ
ingredi
tradit
chines
remedi
danggui
longhui
wan
use
treatment
chronic
myelogen
leukemia
cml
moreov
indirubin
inhibit
glycogen
synthas
kinas
beta
cyclindepend
kinas
cdk
via
bind
atp
pocket
valu
mm
respect
azaindirubin
fig
develop
overcom
poor
water
solubl
henc
low
bioavail
indirubin
show
antiprolif
activ
toward
ovarian
adenoma
cell
line
vein
symmetr
bisisatin
deriv
fig
display
vitro
antiprolif
activ
cell
line
valu
mm
microspher
carrier
system
made
natur
occur
biodegrad
polym
attract
consider
attent
sever
year
field
sustain
drug
deliveri
carrier
system
precis
control
releas
rate
target
drug
specif
bodi
site
enorm
impact
formul
develop
novel
drug
deliveri
system
biodegrad
polyest
copolym
lactic
glycol
acid
plga
attract
biomateri
encapsul
pharmaceut
bioactiv
compound
case
encapsul
drug
readili
avail
biolog
system
solut
releas
drug
occur
onset
polymer
degrad
context
certain
potenti
function
schiff
base
isatin
design
synthes
evalu
vitro
antiprolif
activ
panel
human
cancer
cell
line
addit
nonsymmetr
bisisatin
also
prepar
evalu
new
antiprolif
agent
compound
exhibit
best
pharmacolog
activ
subject
deeper
pharmacolog
investig
order
gain
insight
pharmacolog
profil
well
possibl
mechan
action
moreov
compound
encapsul
plga
microspher
order
evalu
influenc
microencapsul
vitro
antiprolif
activ
melt
point
measur
stuart
melt
point
apparatu
uncorrect
infrar
ir
spectra
record
kbr
disk
use
ftir
spectrum
bx
apparatu
perkin
elmer
ct
usa
nmr
spectra
record
bruker
nmr
spectromet
bruker
reinstetten
germani
spectra
run
mhz
spectra
run
mhz
deuter
dimethyl
sulfoxid
chemic
shift
express
valu
ppm
use
solvent
peak
intern
standard
coupl
constant
j
valu
given
hz
abbrevi
use
follow
singlet
doublet
multiplet
mass
spectra
record
use
agil
quadrupol
lcm
esi
electrospray
ioniz
sourc
agil
technolog
palo
alto
ca
usa
element
analys
carri
region
center
microbiolog
biotechnolog
alazhar
univers
cairo
egypt
analyt
thin
layer
chromatographi
tlc
silica
gel
plate
contain
uv
indic
employ
routin
follow
cours
reaction
check
puriti
product
reagent
solvent
purifi
dri
standard
techniqu
compound
b
previous
report
microspher
prepar
poli
llactid
coglycolid
plga
mol
wt
purchas
sigmaaldrich
st
loui
usa
emulsifi
low
molecular
weight
polyvinyl
alcohol
pva
obtain
alfa
aesar
karlsruh
germani
dichloromethan
dcm
purchas
avonchem
unit
kingdom
dimethyl
sulfoxid
dmso
obtain
loba
chemi
mumbai
india
ingredi
use
analyt
grade
cell
line
purchas
american
type
cultur
collect
atcc
stir
solut
mmol
methanol
ml
hydrazin
hydrat
ml
mmol
ad
reaction
mixtur
reflux
one
hour
precipit
filter
wash
methanol
dri
recrystal
glacial
acet
acid
afford
intermedi
catalyt
amount
glacial
acet
acid
ad
equimolar
quantiti
hydrazon
mmol
benzaldehyd
mmol
ethanol
ml
reaction
mixtur
reflux
four
hour
cool
room
temperatur
obtain
precipit
collect
filtrat
dri
recrystal
ethanoldioxan
mixtur
afford
compound
yield
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
isatin
j
hz
j
hz
isatin
j
hz
j
hz
isatin
j
hz
ch
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
arh
arh
ch
oh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
isatin
j
hz
j
hz
isatin
j
hz
ch
oh
nhindol
nmr
ppm
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
isatin
j
hz
j
hz
isatin
j
hz
isatin
j
hz
ch
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
isatin
j
hz
isatin
j
hz
isatin
j
hz
ch
nhindol
nmr
ppm
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
j
hz
isatin
ch
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
isatin
ch
oh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
isatin
ch
oh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
j
hz
isatin
ch
nhindol
nmr
ppm
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
isatin
j
hz
isatin
ch
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
j
hz
isatin
ch
nhindol
nmr
ppm
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
orang
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
isatin
ch
oh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
j
hz
isatin
ch
oh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
j
hz
isatin
j
hz
j
hz
isatin
ch
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
isatin
j
hz
isatin
j
hz
isatin
ch
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
mixtur
intermedi
b
mmol
appropri
mmol
ethyl
alcohol
catalyt
amount
glacial
acet
acid
heat
reflux
six
hour
filter
hot
precipit
wash
ethanol
solid
product
collect
recrystal
ethanoldmf
mixtur
furnish
compound
yield
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
arh
arh
arh
arh
nhindol
nmr
ppm
c
c
ms
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
n
nmr
ppm
arh
j
hz
arh
arh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
arh
j
hz
arh
arh
nhindol
nmr
ppm
c
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
arh
j
hz
arh
j
hz
arh
j
hz
arh
nhindol
nmr
ppm
c
c
ms
mz
anal
calcd
c
h
n
found
c
h
n
hydrazono
red
powder
yield
mp
ir
kbr
nh
c
c
n
nmr
ppm
arh
j
hz
arh
j
hz
arh
j
hz
arh
arh
nhindol
nmr
ppm
arch
arc
c
ms
esi
mz
anal
calcd
c
h
n
found
c
h
n
detail
experiment
procedur
pharmacolog
evalu
synthes
compound
provid
supplementari
materi
plga
microspher
prepar
modifi
emulsionsolv
diffus
method
describ
previous
briefli
dcm
ml
phase
contain
plga
pour
dmso
ml
phase
contain
compound
obtain
ratio
result
organ
phase
ad
dropwis
help
syring
aqueou
phase
ml
contain
wv
pva
use
magnet
stirrer
rpm
homogen
rpm
room
temperatur
min
result
emuls
transfer
water
ml
room
temperatur
stir
rpm
magnet
stirrer
overnight
solvent
evapor
result
plga
microspher
recov
centrifug
rpm
use
k
centrifug
sigma
germani
min
wash
three
time
distil
water
ml
remov
residu
pva
resuspend
distil
water
ml
lyophil
telstar
freezedry
terrassa
spain
pressur
mbar
h
plain
microspher
prepar
similar
manner
except
absenc
compound
dmso
phase
microspher
yield
percentag
yield
microspher
calcul
use
weight
mg
final
product
dri
lyophil
respect
initi
total
weight
mg
drug
polym
use
prepar
emulsifi
process
accord
eq
equat
show
percentag
yield
calcul
encapsul
effici
compound
mg
quantit
weigh
microspher
dissolv
dmso
ml
sonic
min
hcl
ml
ad
precipit
polym
solut
centrifug
rpm
min
supernat
dilut
appropri
analyz
content
spectrophotometr
biochrom
libra
uk
max
nm
determin
content
polym
interfer
absorb
specifi
wavelength
theoret
determin
entir
present
polym
solut
microspher
entrap
effici
determin
formula
respect
measur
conduct
triplic
determin
particl
size
microspher
particl
size
prepar
microspher
measur
use
dynam
light
scatter
particl
size
analyz
model
zetas
nanoz
zen
malvern
instrument
worcestershir
uk
lyophil
microspher
mg
resuspend
distil
water
ml
particl
size
record
triplic
morpholog
character
microspher
investig
morpholog
character
prepar
microspher
mount
onto
doublesid
adhes
tape
attach
aluminum
stub
coat
gold
examin
scan
electron
microscop
sem
jeol
japan
kv
acceler
voltag
secondari
detector
magnif
adjust
clear
imag
surfac
microspher
appear
pictur
record
studi
vitro
releas
microspher
carri
use
vial
method
report
dubey
et
al
compound
contain
mg
equival
compound
suspend
vial
contain
phosphat
buffer
ml
ph
tween
improv
solubl
vial
incub
water
bath
vibrat
horizont
speed
rpm
vitro
releas
assess
intermitt
sampl
vial
ml
predetermin
time
interv
day
replac
volum
ml
fresh
phosphat
buffer
cell
viabil
assay
cell
viabil
assay
perform
describ
section
antiprolif
activ
supplementari
materi
synthet
strategi
adopt
prepar
target
deriv
depict
file
reflux
hydrazin
hydrat
methanol
obtain
correspond
hydrazon
deriv
reaction
hydrazon
differ
substitut
benzaldehyd
ethanol
presenc
catalyt
amount
glacial
acet
acid
furnish
target
deriv
yield
file
ir
spectra
compound
display
absorpt
band
around
indol
nh
group
addit
absorpt
band
carbonyl
group
near
consist
previous
report
one
compound
also
nmr
spectra
reveal
signal
region
ppm
attribut
nh
proton
moieti
addit
signal
methin
proton
ch
n
region
ppm
accord
previous
report
compound
moreov
nmr
spectra
compound
show
signal
reson
around
ppm
characterist
c
carbon
direct
methyl
benzyl
dimethyl
sulfat
benzyl
bromid
carri
presenc
sodium
hydroxid
potassium
carbon
furnish
intermedi
respect
second
group
target
obtain
good
yield
reaction
two
intermedi
appropri
reflux
ethyl
alcohol
use
catalyt
amount
glacial
acet
acid
file
ir
spectra
target
compound
reveal
presenc
characterist
absorpt
band
due
nh
carbonyl
group
moieti
moreov
nmr
spectra
reveal
presenc
singlet
indol
nh
proton
ppm
also
signal
aliphat
proton
compound
b
observ
singlet
signal
around
ppm
benzyl
proton
appear
singlet
signal
close
ppm
twenti
compound
ie
analyz
cancer
cell
growth
inhibitori
activ
studi
carri
use
cell
deriv
human
lung
colon
breast
tumor
cell
respect
initi
assess
activ
test
compound
quadrupl
singl
concentr
solubl
permit
indic
tabl
test
compound
exhibit
antiprolif
activ
cell
averag
growth
inhibit
rang
wherea
compound
stimul
growth
test
cell
line
compound
activ
compound
show
averag
growth
inhibit
therefor
subject
quantit
inhibitori
concentr
determin
cell
growth
inhibitori
activ
toward
cancer
cell
line
result
present
tabl
fig
extra
sumofsquar
f
test
perform
dose
respons
curv
determin
valu
obtain
cell
line
significantli
differ
compound
test
compound
exhibit
best
averag
valu
nearli
threefold
potent
posit
control
sunitinib
averag
valu
therefor
compound
subject
deeper
pharmacolog
investig
order
obtain
insight
pharmacolog
profil
compound
analyz
apoptosi
induc
activ
cancer
cell
studi
carri
use
cell
deriv
human
lung
followup
assess
activ
test
compound
quadrupl
concentr
equival
valu
inhibit
growth
concentr
threefold
concentr
time
cours
rang
h
indic
fig
compound
increas
caspas
activ
h
treatment
respect
lower
test
concentr
effect
caspas
activ
compound
analyz
effect
variou
aspect
cell
cycl
progress
human
cancer
cell
studi
carri
use
cell
deriv
lung
adenocarcinoma
followup
assess
activ
test
compound
use
immunofluoresc
imag
phosphoryl
rb
protein
total
dna
content
cell
determin
cell
cycl
phase
abil
test
compound
affect
cell
cycl
rb
phosphoryl
test
rang
concentr
less
nm
indic
fig
compound
dosedepend
effect
test
paramet
caus
signific
reduct
total
cell
number
h
treatment
valu
valu
h
tabl
reflect
dosedepend
growth
inhibit
observ
homogen
assay
addit
compound
caus
decreas
percentag
cell
phase
cell
cycl
correspond
increas
sphase
suggest
part
compound
effect
growth
may
attribut
decreas
rate
progress
cell
cycl
correspond
decreas
prolifer
similar
posit
control
sunitinib
arrest
may
repres
checkpoint
blockad
wherea
mitot
arrest
may
case
lead
mitot
catastroph
subsequ
program
death
cell
multipl
aberr
nuclei
increas
sphase
cell
without
concomit
phase
fraction
may
indic
rapid
onset
apoptosi
case
compound
cell
cycl
paramet
level
phosphoryl
rb
protein
substanti
reduc
dosedepend
manner
control
test
compound
h
treatment
valu
lower
valu
reduct
cell
number
caus
test
compound
tabl
may
support
hypothesi
inhibit
cyclin
depend
kinas
isatin
compound
play
role
growth
inhibitori
activ
howev
correl
less
appar
h
time
point
furthermor
compound
analyz
effect
total
cellular
level
phosphoryl
tyrosin
ptyr
residu
human
cancer
cell
studi
carri
use
cell
deriv
lung
adenocarcinoma
immunofluoresc
imag
abil
test
compound
affect
acut
serum
stimul
tyrosin
phosphoryl
test
rang
concentr
less
nm
compound
increas
ptyr
level
nearli
twofold
appar
valu
consist
growth
inhibitori
valu
compound
contrast
posit
control
compound
sunitinib
caus
modest
dosedepend
decreas
level
cellular
tyrosin
phosphoryl
activ
valu
well
growth
inhibitori
fig
indic
select
tumor
cell
compound
analyz
cell
growth
inhibitori
activ
three
nontumorigen
cell
cell
deriv
rat
intestin
exhibit
morpholog
karyotyp
featur
normal
intestin
epitheli
cell
cultur
deriv
human
fibrocyst
mammari
tissu
nontumorigen
exhibit
featur
primari
cultur
breast
tissu
includ
dome
format
fibroblast
deriv
embryon
tissu
mice
swiss
fibroblast
nontumorigen
contact
inhibit
comparison
human
nonsmal
cell
lung
cancer
nsclc
cell
line
includ
assess
growth
inhibitori
activ
compound
test
quadrupl
maximum
concentr
follow
serial
dilut
concentr
indic
fig
tabl
compound
inhibit
growth
normal
tumor
cell
line
compound
display
select
valu
posit
control
sunitinib
show
select
valu
differ
mean
nontumor
cell
line
versu
nsclc
cell
compound
analyz
cancer
cell
growth
inhibitori
activ
sensit
nsclc
cell
line
multidrug
resist
lung
cancer
cell
line
express
efflux
pump
protein
assess
activ
test
compound
quadrupl
maximum
concentr
follow
serial
dilut
concentr
indic
fig
tabl
compound
inhibit
growth
sensit
resist
cell
line
valu
respect
resist
cell
line
nearli
eightfold
less
sensit
indic
compound
may
subject
efflux
posit
control
sunitinib
show
lesser
degre
resist
ie
resist
cell
line
less
sensit
prepar
microspher
high
yield
ww
recoveri
respect
initi
amount
polym
use
microspher
formul
averag
encapsul
effici
plga
microspher
use
polym
ratio
high
encapsul
effici
may
due
presenc
high
amount
polym
reduc
loss
fabric
process
percentag
capac
ftir
spectra
pure
plga
physic
mixtur
plain
microspher
microspher
obtain
verifi
chemic
interact
polym
function
group
band
remain
spectra
pure
well
physic
mixtur
formul
indic
interact
took
place
polym
ftir
spectrum
microspher
found
signific
spectral
shift
disappear
band
spectrum
polym
shown
fig
indic
compat
plga
polym
particl
size
drugload
microspher
consid
import
characterist
could
affect
drug
releas
properti
particl
size
determin
reveal
produc
microspher
uniform
size
rang
small
polydispers
index
pdi
suggest
size
distribut
particl
fairli
monomod
fig
load
alter
particl
size
averag
particl
size
plain
microspher
load
microspher
respect
mean
sd
n
fig
show
particl
size
distribut
microspher
around
narrow
particl
size
distribut
import
aspect
passiv
target
microspher
well
stabil
issu
result
demonstr
particl
size
prepar
microspher
uniform
scan
electron
microscop
sem
imag
reveal
microspher
intact
sphere
show
format
spheric
smooth
surfac
microspher
almost
pore
caviti
may
prolong
releas
encapsul
extend
period
time
crystal
detect
clog
deform
fragment
polym
adher
shown
fig
differ
observ
morpholog
properti
microspher
due
presenc
compound
particl
size
observ
sem
consist
obtain
zetas
particl
size
analyz
result
indic
effici
prepar
method
optim
prepar
paramet
concentr
viscos
polym
solut
obtain
result
consist
previous
report
studi
differ
drug
drug
releas
biodegrad
polymer
particl
occur
combin
sever
mechan
gener
occur
desorpt
surfacebound
drug
diffus
drug
polymer
matrix
eros
polym
particl
vitro
releas
assess
phosphat
buffer
ph
contain
surfact
simul
physiolog
milieu
maintain
sink
condit
sampl
incub
amount
determin
use
uv
spectrophotomet
fig
show
releas
profil
raw
powder
prepar
microspher
linear
prolong
releas
rate
microspher
observ
day
without
initi
burst
releas
fig
hand
releas
compound
raw
powder
faster
releas
microspher
releas
day
uncontrol
burst
releas
compound
raw
powder
could
result
high
local
concentr
could
lead
sever
local
tissu
injur
hamper
appropri
deliveri
target
seen
microspher
exhibit
biphas
drug
releas
kinet
initi
releas
h
six
day
follow
cumul
releas
day
initi
burst
releas
observ
suggest
low
densiti
surfac
microspher
henc
homogen
distribut
within
microspher
high
polym
concentr
led
format
dens
polym
matrix
structur
microspher
pore
observ
sem
imag
result
signific
decreas
initi
burst
releas
microspher
kinet
releas
microspher
close
zero
order
model
correl
coeffici
releas
curv
fit
zero
order
kinet
releas
pattern
due
diffus
degrad
microspher
fig
show
initi
slow
releas
microspher
could
attribut
hydrophob
moreov
interact
hydrophob
molecul
polym
matrix
via
hydrophob
bind
forc
might
caus
trap
drug
insid
particl
therefor
slower
releas
rate
releas
load
microspher
gradual
increas
releas
observ
three
day
fig
probabl
due
diffus
drug
present
surfac
microspher
thereaft
constant
releas
observ
may
due
diffus
matrix
eros
mechan
biodegrad
plga
polym
slow
drug
releas
microspher
mayb
due
high
encapsul
drug
low
swell
polym
releas
medium
lead
slow
diffus
drug
particl
polymer
matric
furthermor
degrad
plga
slow
therefor
releas
microspher
may
depend
drug
diffus
plga
surfac
bulk
eros
swell
conclus
compound
slowli
continu
releas
plga
microspher
obviou
burst
releas
behavior
consist
previou
studi
use
plga
microspher
sustain
drug
releas
sever
anticanc
drug
incorpor
microspher
formula
use
studi
human
lung
cancer
cell
line
human
lung
cancer
cell
line
incub
variou
concentr
free
microspher
evalu
antiprolif
activ
assess
effect
cell
viabil
unload
plga
microspher
lack
compound
coincub
cell
line
show
tumor
growth
inhibit
due
plga
microspher
alon
fig
cytotox
free
evalu
h
incub
time
cytotox
observ
low
concentr
h
reduct
cell
viabil
could
seen
moreov
reduct
cell
viabil
note
h
h
incub
respect
almost
total
inhibit
observ
h
incub
remark
reduct
cell
viabil
observ
h
incub
maintain
h
incub
therefor
cytotox
effect
free
need
higher
concentr
obtain
minim
growth
human
lung
cancer
cell
fig
illustr
obtain
result
microspher
incub
human
lung
cancer
cell
incub
period
concentr
similar
free
cytotox
observ
h
incub
reduct
cell
viabil
observ
respect
h
incub
cell
viabil
decreas
respect
concentr
assay
demonstr
entrap
effect
arrest
cell
growth
compar
free
enhanc
cytotox
microspher
observ
increas
incub
time
concentr
depend
manner
therefor
decreas
percentag
cell
viabil
immedi
rather
gradual
continu
due
polym
allow
slow
releas
microspher
henc
gradual
cytotox
effect
extend
activ
microspher
might
explain
fact
adsorb
onto
cell
membran
gener
drug
concentr
gradient
near
cell
surfac
could
favor
penetr
cell
furthermor
cell
phagocyt
microspher
allow
releas
insid
cytoplasm
thu
contribut
sustain
concentr
quantit
vitro
cytotox
microspher
investig
via
determin
valu
toward
compar
free
valu
almost
free
valu
microspher
valu
h
incub
fig
increas
incub
time
microspher
h
result
signific
reduct
valu
approxim
respect
hand
valu
microspher
reduc
approxim
h
respect
compar
valu
free
statist
analysi
reveal
valu
significantli
differ
p
valu
free
activ
mediat
incorpor
microspher
attribut
sustain
releas
shown
fig
microspher
act
reservoir
protect
drug
hydrolysi
provid
sustain
releas
drug
also
contribut
mainten
drug
activ
sever
report
studi
emphas
incorpor
anticanc
drug
deliveri
system
improv
cytotox
effect
synthesi
molecular
character
use
differ
spectroscop
tool
certain
isatinbas
hybrid
describ
compound
subject
vitro
antiprolif
assess
colon
breast
lung
human
cancer
cell
line
activ
congen
preliminari
vitro
antiprolif
screen
compound
show
averag
valu
respect
compar
refer
drug
sunitinib
exhibit
averag
valu
toward
test
human
cancer
cell
line
compound
select
deeper
pharmacolog
test
gain
insight
possibl
vitro
antiprolif
mechan
action
increas
caspas
activ
h
treatment
respect
moreov
compound
decreas
percentag
cell
phase
cell
cycl
correspond
increas
sphase
increas
sphase
cell
without
concomit
phase
fraction
may
indic
rapid
onset
apoptosi
addit
compound
ptyr
level
nearli
twofold
appar
valu
consist
growth
inhibitori
valu
compound
incorpor
biodegrad
plga
microspher
improv
vitro
antiprolif
activ
result
vitro
antiprolif
assay
indic
plga
microspher
exhibit
better
cytotox
compar
free
toward
human
lung
cancer
cell
line
day
incub
